I'll be brief.
I think one big gap that I would like to identify out loud, and I can send more information, are the disutilities that are used to assess the quality of life that is gained with early detection. I was looking at this recently for the disutility.... If you treated someone for a cancer in health economics, you'll apply a certain, “What percentage of quality of life are they living during that treatment period?”
For breast cancer, and probably for many cancers—but I don't treat those, so I just looked at breast cancer—the disutilities during the treatment period are very finite and really limited to a very short period of time, which really does not reflect the patient's experience. I think if there is going to be work done, it will be looking at the disutilities of the real quality of life and the long-term quality of life impacts of our treatments, which span, in some cases, up to a decade after a cancer diagnosis.